Abstract
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Current Pharmaceutical Design
Title:Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Volume: 24 Issue: 9
Author(s): Samir Gorasiya*, Juliet Mushi, Ryan Pekson, Sabesan Yoganathan and Sandra E. Reznik
Affiliation:
- Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John`s University, Queens, NY 11439,United States
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Abstract: Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Export Options
About this article
Cite this article as:
Gorasiya Samir *, Mushi Juliet , Pekson Ryan , Yoganathan Sabesan and Reznik E. Sandra , Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666180130121706
DOI https://dx.doi.org/10.2174/1381612824666180130121706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Drug Safety
Current Pharmaceutical Design Therapy of Chronic Hepatitis C in the Era of Nanotechnology: Drug Delivery Systems and Liver Targeting
Mini-Reviews in Medicinal Chemistry Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Apoptosis in Arthritis
Current Rheumatology Reviews Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Current Approaches in Antiviral Drug Discovery Against the Flaviviridae Family
Current Pharmaceutical Design Viral Disorder or Disordered Viruses: Do Viral Proteins Possess Unique Features?
Protein & Peptide Letters Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of Patient-Specific Hematopoietic Stem and Progenitor Cell Grafts from Pluripotent Stem Cells, In Vitro
Current Molecular Medicine Isolated Scaphotrapeziotrapezoidal (STT) Arthritis
Current Rheumatology Reviews Role of Cytokines in Allograft Rejection
Current Pharmaceutical Design Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Editorial [Hot topic: Alpha-1 Antitrypsin Deficiency: A Disease with Numerous Adverse Effects on Humans (Guest Editors: S. Ghavami, A.J. Halayko and F.J. de Serres)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design